Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
Investing.com -- GSK plc (LON:GSK), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health.
This approval is for the treatment of adults with multiple myeloma that has relapsed or is refractory. This marks the second major approval for Blenrep combinations.
The approval was granted based on the positive results from a Phase 3 trial. This trial evaluated Blenrep in combination with inhibitors and anti-inflammatory treatments.
The trial involved patients with multiple myeloma who had received at least one prior therapy.
GSK reported that the trials showed significant and clinically meaningful results for progression-free survival with Blenrep’s combinations. These results were compared to the current standards of care.
The pharmaceutical company also noted that Blenrep combinations are currently under review in all major global markets. These include the U.S., the European Union, Canada, and Switzerland.
GSK expects to receive more approvals for its blood-cancer treatment throughout the year.